iBio, Inc. Form 10-Q Summary
Reporting period: Three and six months ended December 31, 2011; filed February 14, 2012. The company is a smaller reporting biotechnology company commercializing the iBioLaunch plant-based platform for vaccines and therapeutic proteins through collaborations and licenses.
Financial Results and Position
| Metric | Three Months Ended Dec. 31, 2011 | Six Months Ended Dec. 31, 2011 |
|---|---|---|
| Revenue | $233,832 | $554,180 |
| Operating expenses | $2,907,476 | $5,552,850 |
| Operating loss | $(2,673,644) | $(4,998,670) |
| Net loss | $(1,597,660) | $(1,214,517) |
| Net loss per share | $(0.05) | $(0.04) |
| Operating cash flow | Not separately presented for the quarter | $(2,012,438) |
- Revenue was generated from technology services provided to Fiocruz/Bio-Manguinhos under the yellow fever vaccine collaboration; no comparable revenue was reported in 2010.
- Cash was $623,452 at December 31, 2011, down from $2,843,300 at June 30, 2011. Total current assets were $1.94 million versus $4.30 million at June 30, 2011.
- Total liabilities were $4.71 million, including $4.04 million of accounts payable, $276,802 of accrued expenses, and a $396,509 derivative instrument liability.
- Stockholders’ equity was $305,479, and accumulated deficit was $26.88 million.
- Debt is not identified as a material balance-sheet item in the filing. The company funded operations primarily through equity and warrant issuances.
- Net loss was materially affected by a non-cash derivative gain of $1.09 million for the quarter and $3.79 million for the six-month period.
Material Changes Versus Prior Comparable Period
- Three-month revenue increased from zero to $233,832; six-month revenue increased from zero to $554,180.
- Three-month research and development expense increased 88% to $1.16 million, while six-month research and development expense increased approximately 237% to $2.62 million. The increase primarily reflected new Fraunhofer research agreements and work on the yellow fever vaccine project.
- General and administrative expense increased 40% for the quarter to $1.75 million and 19% for the six-month period to $2.93 million, mainly due to increased stock-based compensation, employee costs, and executive compensation.
- Quarterly net loss improved from $4.71 million to $1.60 million, and six-month net loss improved from $7.53 million to $1.21 million, primarily because the prior-year periods included substantially larger non-cash derivative losses.
- Cash used in operations improved modestly from $2.23 million to $2.01 million for the six-month period, but the company continued to consume cash.
- The derivative liability declined from $4.19 million at June 30, 2011 to $396,509 at December 31, 2011. Its valuation is sensitive to the company’s stock price, volatility, contractual term, and other model inputs.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that cash of approximately $623,000 at December 31, 2011, together with approximately $9.04 million of net proceeds from a January 2012 equity offering, was expected to fund operations until at least the second calendar quarter of 2013.
- On January 13, 2012, the company issued 15.385 million common shares at $0.65 per share and warrants for up to 11.539 million shares, generating approximately $9.04 million in net proceeds. The offering caused down-round adjustments to certain 2008 warrants and is dilutive to existing holders.
- The company remains dependent on future licensing, partnering, milestone, royalty, and equity financing proceeds. Failure to obtain financing could require delaying or reducing development, relinquishing rights, or ceasing operations.
- Product candidates are in preclinical or early clinical development and require additional research, clinical testing, regulatory approval, and commercial validation. The filing does not provide a clear timetable for product commercialization, but states that commercialization is not expected for at least several years.
- The H5N1 influenza vaccine Phase 1 trial was ongoing, with results expected during the first half of calendar year 2012. The company reported positive interim results for its H1N1 Phase 1 trial in June 2011.
- The company recorded approximately $1.39 million of share-based compensation for the six-month period. A modification to option terms generated an estimated $633,000 incremental charge, of which approximately $451,000 was recorded during the quarter.
- Management concluded that disclosure controls were ineffective as of December 31, 2011. The independent registered public accounting firm identified a material weakness related to the accounting for modified option terms and errors in calculating the resulting stock-based compensation.
- The company had been below an NYSE Amex continued-listing standard related to losses and financial resources. The exchange confirmed on January 27, 2012 that the deficiency was resolved based on the company’s compliance plan and subsequent submissions.
- No material legal proceedings were reported.
Investor Verification Priorities
- Verify the company’s post-quarter financing, including the $9.04 million net proceeds, share issuance, warrant terms, and resulting dilution.
- Assess whether projected liquidity through at least the second quarter of 2013 remains adequate given operating cash burn and outstanding payables.
- Review the material weakness remediation, subsequent accounting for modified options, and the reliability of stock-based compensation disclosures.
- Evaluate the derivative warrant liability and the potential volatility of future reported earnings from changes in its fair value.
- Track clinical, regulatory, and partnering milestones for the H1N1, H5N1, yellow fever, and other vaccine and therapeutic candidates.
- Review obligations under the Fraunhofer Technology Transfer Agreement and related research arrangements, including required payments and minimum annual royalty obligations.